Conference
Results of a randomized, double-blind, placebo-controlled, phase 2 study, investigating the safety and efficacy of anti-factor XIIa monoclonal antibody garadacimab (CSL312) for prophylaxis of HAE
Authors
Craig T; Magerl M; Levy DS; Reshef A; Lumry WL; Martinez-Saguer I; Jacobs JS; Yang WH; Ritchie B; Aygoeren-Puersuen E
Volume
75
Pagination
pp. 61-61
Publisher
WILEY
Publication Date
8 2020
Name of conference
European-Academy-of-Allergology-and-Clinical-Immunology Digital Congress (EAACI)
Conference place
ENGLAND, London
Conference start date
June 6, 2020
Conference end date
June 8, 2020
Conference proceedings
ALLERGY
ISSN
0105-4538